UPC Analytics
ENDE
Analytics1Cases1Decisions3Judges4Parties6Firms
Filing trendsOutcomesPendencyTechnologyForum strategyLeading casesLegal issuesSecurity for costs

Outcome base rates

What's normal — PI grant rate, infringement rate, revocation rate, settlement rate. Honest denominators using motion type.

CategoryrevocationLegal principleclosest prior art identificationClear all
Patentee win rate
Share of merits decisions where the patentee prevailed — infringement cases finding infringement, revocation cases upholding the patent. Settled, withdrawn, and procedural-only outcomes excluded from the denominator.
100%patentees prevail on the merits

1 merits decision (small sample)

1 won · 0 lost · Insufficient prior-period data

Win rate by year
Patentee win rate by year of first decision.
  • 2024: 100% (1/1)
Win rate by division
Top divisions by merits-decision volume.
  • Paris CD
    100%
    (n=1)
PI grant rate
—
PI grant rate (conservative)
—
Infringement rate
—
Revocation rate
0%
0 revoked / partially · 1 maintained / amended
Settlement / withdrawal rate
Settled / withdrawn / dismissed as a share of all non-pending outcomes.
0% 0 / 1
Outcomes by category (detailed)
Stacked breakdown using sharper outcome enums — revocation cases split into revoked_full / revoked_partial / maintained_as_*, etc.
By technology sector
Top sectors by case count (filter scope applied).
By case category
How outcome rates differ across the six L2 buckets.
  • Revocation1
By division
PI grant rate · infringement rate · revocation rate per division (within scope).
  • Paris CD1 casesPI grant rate: —Infringement rate: —Revocation rate: 0%
Recent decisions
Most recent decisions in scope.
  • 2024-07-19CC_585030/2023Patent amendedDecision of the Paris Central Division rejecting the revocation action by Meril Italy Srl and the counterclaims for revocation by Meril GmbH and Meril Life Sciences Pvt Ltd against Edwards Lifesciences Corporation's EP 3 646 825 (prosthetic heart valve). The patent is maintained as amended in auxiliary request II, which limits claims to a frame made up entirely of hexagonal cells. The revocation claimants (60%) and defendant (40%) share costs.